Nathan W. Furukawa

Nathan W. Furukawa

Auto-generated profile, based on publicly available information

Nathan W. Furukawa

Division of Viral Hepatitis, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention , Atlanta, Georgia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Emerging Infectious Diseases
Verified
Journal Article
Closed access
NFNathan W. Furukawa
Nathan W. Furukawa
JBJohn T. Brooks
John T. Brooks
JSJeremy Sobel
Jeremy Sobel
Transmission of SARS-CoV-2 While Asymptomatic

4 May 2020 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
NFNathan W. Furukawa
Nathan W. Furukawa
JMJessica L. Maksut
Jessica L. Maksut
MZMaria Zlotorzynska
Maria Zlotorzynska
TSTravis H. Sanchez
Travis H. Sanchez
DSDawn K. Smith
Dawn K. Smith
SBStefan D. Baral
Stefan D. Baral

15 November 2019 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
CRChulwoo Rhee
Chulwoo Rhee
GKGrishma A. Kharod
Grishma A. Kharod
NSNicolas Schaad
Nicolas Schaad
NFNathan W. Furukawa
Nathan W. Furukawa
NVNeil M. Vora
Neil M. Vora
KCKevin R. Clarke
Kevin R. Clarke
Acute febrile illness (AFI), a common reason for people seeking medical care globally, represents a spectrum of infectious disease etiologies with important variations geographically and by population. There is no standardized approach to conducting AFI etiologic investigations, limiting interpretation of data in a global context. We conducted a scoping review to characterize current AFI research methodologies, identify global research gaps, and provide methodological research standardization recommendations. Using pre-defined terms, we searched Medline, Embase, and Global Health, for publications from January 1, 2005–December 31, 2017. Publications cited in previously published systematic reviews and an online study repository of non-malarial febrile illness etiologies were also included. We screened abstracts for publications reporting on human infectious disease, aimed at determining AFI etiology using laboratory diagnostics. One-hundred ninety publications underwent full-text review, using a standardized tool to collect data on study characteristics, methodology, and laboratory diagnostics. AFI case definitions between publications varied: use of self-reported fever as part of case definitions (28%, 53/190), fever cut-off value (38·0°C most commonly used: 45%, 85/190), and fever measurement site (axillary most commonly used: 19%, 36/190). Eighty-nine publications (47%) did not include exclusion criteria, and inclusion criteria in 13% (24/190) of publications did not include age group. No publications included study settings in Southern Africa, Micronesia & Polynesia, or Central Asia. We summarized standardized reporting practices, specific to AFI etiologic investigations that would increase inter-study comparability. Wider implementation of standardized AFI reporting methods, with multi-pathogen disease detection, could improve comparability of study findings, knowledge of the range of AFI etiologies, and their contributions to the global AFI burden. These steps can guide resource allocation, strengthen outbreak detection and response, target prevention efforts, and improve clinical care, especially in resource-limited settings where disease control often relies on empiric treatment. PROSPERO: CRD42016035666. Acute febrile illness (AFI) is a common reason for people seeking medical care globally with potentially serious infectious etiologies. However, AFI has no current consensus standardized approach when considered as a syndromic case definition for public health surveillance or research, especially in global settings where AFI treatment is performed with limited diagnostic availability. Therefore, the aim of this review was to describe current methodologies in AFI research, identify gaps in research, and provide recommendations for standardization of AFI research. We screened abstracts and completed full-text reviews on publications found through an extensive search. A total of 190 publications were included in the final review, from which we collected data on study characteristics, methodology, and laboratory diagnostics. These collected data elements allowed us to identify where there were inconsistencies in reporting and investigative methods, which data elements were not regularly collected, and what laboratory testing methods were commonly used. Standardized reporting methods for AFI investigations, along with laboratory testing capacity for multiple pathogens, can improve our knowledge of the causative agents of AFI in certain regions of the world. This can help us determine where resources are needed, how to strengthen outbreak detection and response, and how to improve medical care, especially in regions with limited resources.

6 February 2020 in Public Health Reports®
Verified
Journal Article
Open access
PDF file
NFNathan W. Furukawa
Nathan W. Furukawa
DSDawn K. Smith
Dawn K. Smith
CGCharles J. Gonzalez
Charles J. Gonzalez
YHYa-Lin A. Huang
Ya-Lin A. Huang
DHDavid B. Hanna
David B. Hanna
VPViraj V. Patel
Viraj V. Patel
Objective: Daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) use as HIV preexposure prophylaxis (PrEP) is monitored by identifying TDF/FTC prescriptions from pharmacy databases and applying diagnosis codes and antiretroviral data to algorithms that exclude TDF/FTC prescribed for HIV postexposure prophylaxis (PEP), HIV treatment, and hepatitis B virus (HBV) treatment. We evaluated the accuracy of 3 algorithms used by the Centers for Disease Control and Prevention (CDC), Gilead Sciences, and the New York State Department of Health (NYSDOH) using a reference population in Bronx, New York. Methods: We extracted diagnosis codes and data on all antiretroviral prescriptions other than TDF/FTC from an electronic health record database for persons aged ≥16 prescribed TDF/FTC during July 2016–June 2018 at Montefiore Medical Center. We reviewed medical records to classify the true indication of first TDF/FTC use as PrEP, PEP, HIV treatment, or HBV treatment. We applied each algorithm to the reference population and compared the results with the medical record review. Results: Of 2862 patients included in the analysis, 694 used PrEP, 748 used PEP, 1407 received HIV treatment, and 13 received HBV treatment. The algorithms had high specificity (range: 98.4%-99.0%), but the sensitivity of the CDC algorithm using a PEP definition of TDF/FTC prescriptions ≤30 days was lower (80.3%) than the sensitivity of the algorithms developed by Gilead Sciences (94.7%) or NYSDOH (96.1%). Defining PEP as TDF/FTC prescriptions ≤28 days improved CDC algorithm performance (sensitivity, 95.8%; specificity, 98.8%). Conclusions: Adopting the definition of PEP as ≤28 days of TDF/FTC in the CDC algorithm should improve the accuracy of national PrEP surveillance.

1 July 2024 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
NFNathan W. Furukawa
Nathan W. Furukawa
SISusan Z. Ingber
Susan Z. Ingber
HSHasan Symum
Hasan Symum
KRKarina K. Rapposelli
Karina K. Rapposelli
ETEyasu H. Teshale
Eyasu H. Teshale
NGNeil Gupta
Neil Gupta
Since 2014, use of oral direct-acting antivirals (DAAs) has been the standard of care for hepatitis C and results in cure rates of greater than 95% with 8 to 12 weeks of treatment.1 Although the US has a goal of eliminating hepatitis C as a public health threat by 2030, the number of estimated new hepatitis C virus (HCV) infections has more than doubled from 24 700 in 2012 to 69 800 in 2021.2,3 After an initial surge of people being treated after the release of DAAs, the number of people treated for hepatitis C has steadily declined from a peak of 164 247 people in 2015 to 83 740 people in 2020.4 Previous modeling has suggested that a mean of 260 000 people must be treated each year to reach hepatitis C elimination targets.5 Despite an estimate of more than 1 million people treated with DAAs in the US since 2014, only 34% of people with diagnosed infection had evidence of viral clearance, and the number of people with hepatitis C nationally remained stable from 2.1 million in 2013 to 2016 to 2.2 million in 2017 to 2020.6,7 Many more people with hepatitis C need to be treated to reach national hepatitis C elimination targets.

1 June 2021 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
NFNathan W Furukawa
Nathan W Furukawa
EBErin F Blau
Erin F Blau
ZRZach Reau
Zach Reau
DCDavid Carlson
David Carlson
ZRZachary D Raney
Zachary D Raney
SLSheryl B Lyss
Sheryl B Lyss
Background: Persons who inject drugs (PWID) have frequent healthcare encounters related to their injection drug use (IDU) but are often not tested for human immunodeficiency virus (HIV). We sought to quantify missed opportunities for HIV testing during an HIV outbreak among PWID. Methods: PWID with HIV diagnosed in 5 Cincinnati/Northern Kentucky counties during January 2017–September 2018 who had ≥1 encounter 12 months prior to HIV diagnosis in 1 of 2 Cincinnati/Northern Kentucky area healthcare systems were included in the analysis. HIV testing and encounter data were abstracted from electronic health records. A missed opportunity for HIV testing was defined as an encounter for an IDU-related condition where an HIV test was not performed and had not been performed in the prior 12 months. Results: Among 109 PWID with HIV diagnosed who had ≥1 healthcare encounter, 75 (68.8%) had ≥1 IDU-related encounters in the 12 months before HIV diagnosis. These 75 PWID had 169 IDU-related encounters of which 86 (50.9%) were missed opportunities for HIV testing and occurred among 46 (42.2%) PWID. Most IDU-related encounters occurred in the emergency department (118/169; 69.8%). Using multivariable generalized estimating equations, HIV testing was more likely in inpatient compared with emergency department encounters (adjusted relative risk [RR], 2.72; 95% confidence interval [CI], 1.70–4.33) and at the healthcare system receiving funding for emergency department HIV testing (adjusted RR, 1.76; 95% CI, 1.10–2.82). Conclusions: PWID have frequent IDU-related encounters in emergency departments. Enhanced HIV screening of PWID in these settings can facilitate earlier diagnosis and improve outbreak response.